Research Article

Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

Figure 3

The correlation of irAEs with progression-free survival (PFS). (a) In total patients, the irAE group and non-irAE group. (b) In total patients, the irAE group and other patients group within 3 months. (c) In total patients, irAEs of the grade ≥2 group and irAEs of the grade 1 or non-irAE group. (d) In total patients, the endocrine AEs group and other patients group. (e) In total patients, the “single-site” irAE or non-irAEs group and “multi-site” irAE group. (f) In the irAE subgroup, the “single-site” irAE group and “multi-site” irAE group. (g) In patients with lung cancer, the irAE group and non-irAE groups.
(a)
(b)
(c)
(d)
(e)
(f)
(g)